RPA Software: Blue Prism, UiPath, & Automation Anywhere
Former VP at Accenture and EPAM Systems
inpractise.com/articles/rpa-software-prsm-uipath-aa
Why is this interview interesting?
- How RPA software is deployed at the client
- The difference between on-premise and cloud-native solutions
- Why UiPath has an advantage over Blue Prism
- Pricing differences between Blue Prism and UiPath
- What drives differentiation in RPA software
- Potential competitive risk from cloud providers
RPA Software: Blue Prism, UiPath, & Automation Anywhere(September 25, 2020)
Daniel Song
Former VP at Accenture and EPAM Systems
Daniel has 20 years of experience as a technology consultant working on large enterprise digital transformations. He has spent the last 7 years helping enterprise clients choose and utilise leading RPA vendors such as Blue Prism, UiPath, and Automation Anywhere for robotic-processing automation and AI solutions. Daniel previously worked at EPAM Systems as Global Head of Business Consulting and has spent a decade working at Accenture and IBM leading digital transformation projects. Daniel is currently the Chief Innovation Officer at HealthRede, a technology consultancy firm specializing in RPA and AI solutions.
Interview Transcript
This is a snippet of the transcript, sign up to read more.
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2023 IP 1 Ltd. All rights reserved.